|Bid||5.30 x 800|
|Ask||5.31 x 1400|
|Day's Range||5.29 - 5.55|
|52 Week Range||4.25 - 13.31|
|Beta (3Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 29, 2019 - Aug 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.
Is Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]
Lonnel Coats has been the CEO of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) since 2014. This analysis aims first to...
Lexicon Pharmaceuticals Inc NASDAQ/NGS:LXRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for LXRX with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding LXRX is favorable, with net inflows of $2.55 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Lexicon Pharmaceuticals, Inc. (LXRX), today announced new analyses of clinical data for sotagliflozin will be presented at the upcoming 79th American Diabetes Association (ADA) Scientific Sessions in San Francisco, California. The five accepted posters reflect Lexicon and its collaborator, Sanofi’s efforts to address the unmet need and potential treatment options for the management of type 1 diabetes.
A live audio webcast for this conference will be available in the “Events” section of the Lexicon website at www.lexpharma.com/. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. In addition to its first commercial product, XERMELO® (telotristat ethyl), Lexicon has a pipeline of promising drug candidates in clinical and pre-clinical development in diabetes and metabolism and neuropathic pain.
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -31.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the The Woodlands, Texas-based company said it had a loss of 21 cents. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
THE WOODLANDS, Texas, May 01, 2019 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended.
Zynquista TM now approved in the European Union for treatment of adults with type 1 diabetes PARIS and THE WOODLANDS, TX - April 26, 2019 - The European Commission has granted marketing authorization for ...
PARIS and THE WOODLANDS, Texas, April 26, 2019 -- The European Commission has granted marketing authorization for Zynquista™ (sotagliflozin)*, developed by Sanofi and Lexicon.
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lexicon Pharmaceuticals, Inc. (LXRX), will release its first quarter 2019 financial results on Wednesday, May 1, 2019 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss the financial results and to provide a business update.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But l...
NEW YORK, April 01, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company") (LXRX) of the April 1, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com.
NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc. ("Lexicon" or ...
NEW YORK, March 29, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.